You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Dow
Boehringer Ingelheim
Harvard Business School
Medtronic

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,549,941

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,549,941 protect, and when does it expire?

Patent 9,549,941 protects SOVALDI and is included in one NDA.

Protection for SOVALDI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety patent family members in forty countries.

Summary for Patent: 9,549,941
Title:Compositions and methods for treating hepatitis C virus
Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
Inventor(s): Cleary; Darryl G. (Chapel Hill, NC), Reynolds; Charles J. (Greenville, NC), Berrey; Miriam Michelle (Durham, NC), Hindes; Robert G. (Skillman, NJ), Symonds; William T. (San Francisco, CA), Ray; Adrian S. (Redwood City, CA), Mo; Hongmei (Palo Alto, CA), Hebner; Christy M. (Belmont, CA), Oliyai; Reza (Burlingame, CA), Zia; Vahid (San Carlos, CA), Stefanidis; Dimitrios (Mountain View, CA), Pakdaman; Rowchanak (San Carlos, CA), Casteel; Melissa Jean (Burlingame, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:14/538,736
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,549,941
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,549,941

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Mallinckrodt
Merck
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.